Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CAR-T Meeting 2024

The EBMT-EHA 6th European CAR T-cell Meeting

15–17 February 2024 | Valencia, Spain / Online

Jointly organized by the EBMT and EHA, the 6th European CAR T-cell Meeting took place on February 15-17, 2024, in Valencia, Spain, and online, and covered the latest clinical and translational advances in CAR-T therapy.

View all videos

T2Evolve: identifying and addressing the needs and gaps in CAR-T therapy

Carmen Sanges • 29 Feb 2024

The role of AI in medicine and how acceptance and trust in AI strategies can be fostered

Carmen Sanges • 29 Feb 2024

KCAT19: an off-the-shelf cord blood-derived allogeneic CAR-T product without genome editing

Giulia Agliardi • 26 Feb 2024

The need for alternative development pathways for CAR T-cell products

Andre Baruchel • 16 Feb 2024

CAR-T in myeloma: will it provide a cure?

Borja Puertas • 16 Feb 2024

The factors associated with poor outcomes following CAR-T in patients with myeloma

Luis-Esteban Tamariz-Amador • 20 Feb 2024

The need for alternative development pathways for CAR T-cell products

Andre Baruchel • 16 Feb 2024

Engineering donor-derived CAR-CIK cells towards B-ALL multi-targeting using Sleeping Beauty platform

Alex Moretti • 16 Feb 2024

The risk of secondary malignancies following CAR T-cell therapy: current evidence

Anna Sureda • 7 Mar 2024

The future of CAR-T for the treatment of lymphoma

Anna Sureda • 7 Mar 2024

First-in-human Phase I trial of AT101, a novel anti-CD19 CAR-T, in R/R NHL

Marco Ruella • 16 Feb 2024

A summary of the prognostic factors that can influence the outcomes of anti-CD19 CAR-T in R/R DLBCL

Anna Sureda • 7 Mar 2024